Home About Login Current Archives Announcements Editorial Board
Submit Now For Authors Call for Submissions Statistics Contact
Home > Archives > Volume 20, No 8 (2022) > Article

DOI: 10.14704/nq.2022.20.8.NQ44773

Special considerations for leukemic patients during the COVID-19 pandemic: meta-analysis study

Nasser Ghaly Yousif*, Jacklyn Fullerton, Viviana Cabrera


Patients with acute leukemia have an increased risk for severe COVID-19 disease and mortality. Treating patients with acute leukemia (ALL and AML) during a COVID-19 pandemic can be particularly challenging. The coronavirus disease 2019 (COVID-19) pandemic poses several challenges to the management of patients with leukemia. An important distinction is the prevalence of exposure versus clinical infectivity, which determine the risk versus benefit of modifying potentially highly curative therapies in leukemia. At present, the rate of mortality in cancer patients >30%, that needs careful consideration given to the risk of COVID-19 in leukemia. The goal of this study was to determine offer recommendations on the optimization of leukemia management during high-risk COVID-19 periods.


Acute leukemia, COVID-19, Meta-analysis

Full Text